{"entity":{"id":"nct06907043","kind":"trial","name":"A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.","aka":[],"tldr":"A phase 1/2 trial of EIK1004-001 (IMP1707-001) in advanced solid tumours, run by Eikon Therapeutics, now recruiting.","summary":"A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors. is a phase 1/2 interventional study registered as NCT06907043 by Eikon Therapeutics, with 130 participants planned, started 2025-04-30 and due to reach its primary completion in 2028-12. Interventions recorded: EIK1004-001 (IMP1707-001).","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06907043","url":"https://clinicaltrials.gov/study/NCT06907043"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["eikon-therapeutics","impact-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06907043","phase":"1/2","setting":"A Phase 1/2, Open-label, Multicenter, Dose-escalation, and Dose-Optimization Study to Evaluate the Safety, Tolerability, and Activity of EIK1004 (IMP1707) as Monotherapy in Participants With Advanced Solid Tumors","sponsor":"Eikon Therapeutics","enrolled":130,"outcomes":[]},"route":"/trials/nct06907043/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"eikon-therapeutics","kind":"company","name":"Eikon Therapeutics","route":"/companies/eikon-therapeutics/"},{"id":"impact-therapeutics","kind":"company","name":"IMPACT Therapeutics","route":"/companies/impact-therapeutics/"}]}}